Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2450 + anlotinib + chemotherapy
- Development stage
- Unknown
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous (TQB2450, Chemotherapy), Oral (anlotinib)
01
Overview
TQB2450 + anlotinib + chemotherapy is a multi-agent combination regimen investigated primarily for various advanced cancers. TQB2450 (Benmelstobart) is a humanized IgG1 monoclonal antibody targeting PD-L1, designed to inhibit immune checkpoint pathways and enable anti-tumor immune responses. Anlotinib is an oral, small molecule multitargeted tyrosine kinase inhibitor that blocks pro-angiogenic pathways, including VEGFR1-3, PDGFR-β, FGFR1, and c-Kit, thus inhibiting tumor angiogenesis and proliferation. The "chemotherapy" component varies per study, commonly including agents such as paclitaxel and cisplatin. The combination is evaluated in diseases such as limited-stage and extensive-stage small-cell lung cancer (SCLC), advanced esophageal squamous cell carcinoma (ESCC), and other solid tumors. The strategy aims to synergistically target the tumor microenvironment through immunotherapy, anti-angiogenesis, and cytotoxic mechanisms for improved tumor control and survival[1][2][3][4][5].
- Brand names
- Benmelstobart
- Other names
- TQB2450 + anlotinib + chemotherapy
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))PDGFRB (Platelet-derived growth factor receptor beta)CD274 (Programmed cell death protein 1 ligand 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on TQB2450 + anlotinib + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2450 + anlotinib + chemotherapy.